The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Heart failure is a global pandemic affecting an estimated 26 million people worldwide and
resulting in more than 1 million hospitalizations annually in both the United States and …

Cardiovascular disease is the leading cause of death in women. Decades of grassroots
campaigns have helped to raise awareness about the impact of cardiovascular disease in …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

Background The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan led to a
reduced risk of hospitalization for heart failure or death from cardiovascular causes among …

Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …

Background SGLT2 inhibitors are strongly recommended in guidelines to treat patients with
heart failure with reduced ejection fraction, but their clinical benefits at higher ejection …

Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF)
remains a challenge. We recommend a new stepwise diagnostic process, the 'HFA–PEFF …

Summary of Key Points In this document, we propose a universal definition of heart failure
(HF) as the following: HF is a clinical syndrome with symptoms and or signs caused by a …